X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (812) 812
humans (747) 747
oncology (512) 512
open-label (371) 371
randomized phase-3 trial (327) 327
female (320) 320
male (297) 297
chemotherapy (294) 294
randomized controlled trials as topic (248) 248
middle aged (243) 243
treatment outcome (237) 237
double-blind (225) 225
1st-line treatment (224) 224
cancer (222) 222
aged (215) 215
phase-3 trial (199) 199
care and treatment (189) 189
adult (177) 177
analysis (148) 148
randomized phase-3 (145) 145
survival (136) 136
phase-3 (132) 132
randomized-trial (129) 129
antineoplastic agents - therapeutic use (128) 128
therapy (125) 125
clinical trials (124) 124
mutation (124) 124
patients (124) 124
hematology (123) 123
metastasis (123) 123
randomized controlled-trial (123) 123
antineoplastic combined chemotherapy protocols - therapeutic use (122) 122
pharmacology & pharmacy (121) 121
multicenter (118) 118
gefitinib (112) 112
medicine & public health (107) 107
disease-free survival (104) 104
erlotinib (103) 103
adenocarcinoma (100) 100
aged, 80 and over (96) 96
lung neoplasms - drug therapy (88) 88
efficacy (87) 87
drug therapy (85) 85
lung cancer (84) 84
prognosis (84) 84
research (82) 82
protein kinase inhibitors - therapeutic use (81) 81
surgery (79) 79
retrospective studies (78) 78
lung neoplasms - genetics (72) 72
hematology, oncology and palliative medicine (71) 71
neoplasm staging (71) 71
medicine, general & internal (70) 70
quality-of-life (69) 69
review (69) 69
safety (69) 69
carcinoma, non-small-cell lung - drug therapy (68) 68
placebo-controlled trial (68) 68
risk factors (66) 66
health aspects (65) 65
breast cancer (64) 64
immunotherapy (64) 64
survival analysis (64) 64
bortezomib (63) 63
cancer therapies (62) 62
cell lung-cancer (62) 62
multiple myeloma (62) 62
stem-cell transplantation (62) 62
immunology (61) 61
meta-analysis (60) 60
respiratory system (59) 59
bevacizumab (58) 58
epidermal growth factor (58) 58
growth-factor receptor (58) 58
medical research (58) 58
receptor, epidermal growth factor - genetics (58) 58
studies (58) 58
carcinoma, non-small-cell lung - genetics (57) 57
controlled phase-3 trial (57) 57
egfr mutations (57) 57
patient outcomes (57) 57
tyrosine kinase inhibitors (57) 57
radiotherapy (56) 56
urology & nephrology (56) 56
quality of life (55) 55
lung neoplasms - pathology (54) 54
afatinib (53) 53
non-small cell lung cancer (53) 53
respiratory tract diseases (53) 53
genetic aspects (52) 52
lung cancer, non-small cell (52) 52
multiple sclerosis (52) 52
tyrosine (52) 52
acquired-resistance (51) 51
animals (51) 51
survival rate (51) 51
abridged index medicus (50) 50
clinical trials, phase iii as topic (50) 50
disease progression (50) 50
usage (50) 50
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 04/2015, Volume 107, Issue 4
Journal Article
European Urology, ISSN 0302-2838, 2016, Volume 71, Issue 3, pp. 447 - 461
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016, Volume 96, Issue 2, pp. 259 - 265
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 06/2018, Volume 29, Issue 6, pp. 1343 - 1344
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2015, Volume 21, Issue 14, pp. 3196 - 3203
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15, pp. 1737 - 1745
PurposeTo jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account for new evidence.MethodsAn Update... 
THERAPY | BOOST | ONCOLOGY | EXTERNAL-BEAM RADIATION | RANDOMIZED-TRIAL | RADIOTHERAPY | PHASE-3 | DOSE-RATE BRACHYTHERAPY | Brachytherapy - standards | Male | Prostatic Neoplasms - radiotherapy | Humans | Brachytherapy - methods | Randomized Controlled Trials as Topic
Journal Article